Combination talabostat and pembrolizumab has shown antitumor activity in patients who have metastatic castration-resistant prostate cancer with small-cell neuroendocrine carcinoma phenotype.
Prophylaxis against Pneumocystis jirovecii pneumonia with trimethoprim-sulfamethoxazole reduced the risk for severe infections by nearly 77%, a study found.
Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma
Kidney transplant recipients are at high risk for hyperuricemia due to multiple contributing factors.
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Study findings fill in the evidence gap during the current BCG shortage, while data from randomized clinical trials are pending.
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
There is an unmet need for systemic treatment options in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to investigators.
